Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q16555
UPID:
DPYL2_HUMAN
Alternative names:
Collapsin response mediator protein 2; N2A3; Unc-33-like phosphoprotein 2
Alternative UPACC:
Q16555; A8K5H2; B4DR31; D3DSS7; O00424
Background:
Dihydropyrimidinase-related protein 2, also known as Collapsin response mediator protein 2, plays a pivotal role in neuronal development, axon growth, and guidance. It is essential for class 3 semaphorins signaling, influencing cytoskeleton remodeling, neuronal growth cone collapse, and cell migration. Additionally, it may contribute to endocytosis processes.
Therapeutic significance:
Understanding the role of Dihydropyrimidinase-related protein 2 could open doors to potential therapeutic strategies.